@Rhino1963 reply function not...

@Rhino1963 reply function not working

https://www.forbes.com/sites/davidshaywitz/2017/07/26/the-startling-history-behind-mercks-new-cancer-blockbuster/

I think this story is the best example for how quickly things can happen in pharma.

Merck put Keytruda basically in the pharma bin in 2009.

This was until mid 2010, where Merck caught wind that BMS had a PD1 targeting compound.

Work exploded at this point, where it was a race to approval for either Keytruda or Opdivo.

Merck won by 3-months, and in classic first-in-class fashion...

Expected earnings for 2024:
Keytruda USD $28B
Opdivo USD $11B

Bisantrene is starting a 100m race from the 90m line. Research to date demonstrates FTO and m6a levels are very important in 30+ cancer types and 25 different drug classes. If m6A modification proves to synergise with and provide cardioprotection against effective cardiotoxic drugs (like it already has in 2 P2 trials), then I suspect things could get very hot, very quick.

Show me an FTO inhibitor that is clinic ready (you can't), and then explain why it would be an effective competitor if preclinical evidence suggests FTO inhibition (inceased m6A levels) synergises with cardiotoxic drugs to kill HCM.

https://pubmed.ncbi.nlm.nih.gov/38631119/
https://pubmed.ncbi.nlm.nih.gov/38434564/
https://pubmed.ncbi.nlm.nih.gov/38316068/
https://pubmed.ncbi.nlm.nih.gov/38156523/
https://pubmed.ncbi.nlm.nih.gov/37426524/
https://pubmed.ncbi.nlm.nih.gov/36876119/
https://pubmed.ncbi.nlm.nih.gov/35402566/
https://pubmed.ncbi.nlm.nih.gov/34820430/

We are 1 of 1.